Yichen Wang

Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea

L. Mazzolai, A. Hovnanian, M. Gilliet, 2021, JCI insight.

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Acta crystallographica. Section F, Structural biology communications.

Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalities.

J. Bouwstra, A. Hovnanian, J. Aerts, 2020, Journal of lipid research.

Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Bioorganic & medicinal chemistry letters.

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Bioorganic & medicinal chemistry letters.

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

A. Hovnanian, J. Liddle, P. Thomas, 2019, Bioorganic & medicinal chemistry letters.

A potent and selective Kallikrein-5 inhibitor delivers high pharmacological activity in Netherton Syndrome patient skin.

M. Lennon, A. Hovnanian, D. Grillot, 2021, The Journal of investigative dermatology.

Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome

K. Zengler, A. Hovnanian, C. Dupont, 2020, Cell reports.

Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalities[S]

J. Bouwstra, A. Hovnanian, J. Aerts, 2020, Journal of Lipid Research.

Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea

L. Mazzolai, A. Hovnanian, J. Di Domizio, 2023, JCI insight.